Agilent Technologies, Inc. (NYSE:A) Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. trimmed its position in shares of Agilent Technologies, Inc. (NYSE:A) by 0.1% in the fourth quarter, HoldingsChannel reports. The firm owned 8,228,455 shares of the medical research company’s stock after selling 6,734 shares during the period. T. Rowe Price Investment Management Inc.’s holdings in Agilent Technologies were worth $1,105,411,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. CKW Financial Group grew its position in Agilent Technologies by 114.9% in the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after buying an additional 100 shares in the last quarter. Global X Japan Co. Ltd. boosted its holdings in shares of Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 116 shares in the last quarter. Redwood Park Advisors LLC acquired a new position in shares of Agilent Technologies during the fourth quarter valued at approximately $27,000. Lee Danner & Bass Inc. acquired a new position in shares of Agilent Technologies during the fourth quarter valued at approximately $29,000. Finally, Hanson & Doremus Investment Management raised its holdings in Agilent Technologies by 66.5% during the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock worth $35,000 after purchasing an additional 105 shares in the last quarter.

Insiders Place Their Bets

In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $116.46, for a total transaction of $211,840.74. Following the completion of the sale, the director now directly owns 35,737 shares in the company, valued at $4,161,931.02. This represents a 4.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the sale, the vice president now owns 21,786 shares of the company’s stock, valued at approximately $2,657,456.28. The trade was a 8.05 % decrease in their position. The disclosure for this sale can be found here.

Agilent Technologies Price Performance

A opened at $102.83 on Wednesday. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $155.35. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $29.32 billion, a P/E ratio of 23.64, a PEG ratio of 2.83 and a beta of 1.19. The stock has a fifty day moving average of $118.12 and a 200-day moving average of $131.80.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. Equities analysts forecast that Agilent Technologies, Inc. will post 5.54 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be issued a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio is presently 22.76%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on A shares. Jefferies Financial Group lowered their price target on Agilent Technologies from $135.00 to $116.00 and set a “hold” rating on the stock in a research report on Monday. TD Cowen lifted their target price on Agilent Technologies to $135.00 and gave the stock a “buy” rating in a report on Thursday, April 10th. Wells Fargo & Company cut their price target on shares of Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating for the company in a report on Thursday, April 17th. Robert W. Baird lowered their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Finally, Barclays cut their target price on shares of Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Agilent Technologies currently has an average rating of “Moderate Buy” and an average price target of $143.00.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.